XJPX
9273
Market cap208mUSD
Oct 09, Last price
795.00JPY
1D
1.92%
1Q
1.53%
IPO
161.73%
Name
Koa Shoji Holdings Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Koa Shoji Holdings Co.,Ltd., established in 1991 and headquartered in Yokohama, Japan, operates through its subsidiaries, engaging in a diverse array of pharmaceutical activities. The company sources and distributes active pharmaceutical ingredients and their precursors throughout the Japanese market. Additionally, it is involved in the production and commercialization of a range of injectable medications, alongside over-the-counter drugs, with a particular emphasis on vitamin formulations. Koa Shoji Holdings also manufactures and distributes generic pharmaceuticals. Complementing these operations, the firm provides outsourced drug production services and offers specialized packaging solutions for medicinal products.
Key people
Toshihiro Hirono
Vice President, Director · since 2025
Ritsuko Ohtsuka
Vice President, Director · since 2024
Miyoko Komatsu
Managing Director · since 2025
Hiroki Toyoda
Executive Officer, Director of General Affairs · since 2021
Toshinori Koyama
Senior Managing Director · since 2016
Toshiyuki Shuto
President, Chairman of Subsidiaries, Representative Director · since 2021
Teruyuki Tanaka
Director · since 2018
Kyoko Hayashi
Independent Director · since 2023
Yoshitaka Hirao
Independent Director · since 2017
Hiroshi Kinoshita
Independent Director · since 2022
Yuki Yamagishi
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||